Shorter treatment course potentially on the horizon for hep C patients

Posted by on April 15, 2016 12:14 pm
Categories: health

Data from a Phase 2 clinical trial show that an investigational injectable treatment known as RG-101 in combination with a four week course of oral direct-acting antiviral (DAA) treatment was well tolerated and resulted in high virologic response rates post-treatment among hepatitis C (HCV) infected patients with genotypes 1 and 4, who had not been treated previously.

Leave a Reply

Your email address will not be published. Required fields are marked *